Tag: Knight Therapeutics

September 5, 2018

6 Opioid Use Disorder Treatment Stocks

Here the Investing News Network looks at six opioid use disorder treatment stocks. Read on to learn more about them...
September 4, 2018

Investing in Opioid Use Disorder Treatments

Pharmaceutical companies, the healthcare system and the government are facing new realities with the opioid epidemic, and the only positive...
May 17, 2018

“We’re Financially Prudent,” Says CFO and President of Knight Therapeutics Samira Sakhia

At the Bloom Burton & Co. Healthcare Investment Conference held in Toronto from May 2-3, the Investing News Network had...
May 2, 2018

Notes from the Floor: Bloom Burton & Co., Day 1

The Bloom Burton & Co. Healthcare Investor Conference runs from May 2 to 3 in Toronto — here's what happened...
March 19, 2018

Knight Announces Exclusive License Agreement with Ardelyx for Tenapanor

Knight Therapeutics (TSX:GUD) announced today a license agreement with Ardelyx (NASDAQ:ARDX) that provides Knight with exclusive rights to commercialize tenapanor...
March 15, 2018

Knight Reports 2017 Fourth Quarter and Year End Results

Knight Therapeutics (TSX:GUD) a leading Canadian specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended...
February 15, 2018

Knight Therapeutics and SIFI Announce Filing of New Drug Submission

Knight Therapeutics (TSX:GUD) a leading Canadian specialty pharmaceutical company, and S.I.F.I- Società Industria Farmaceutica Italiana S.p.A., a prominent Italian Eye...